Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7094427 | IMPAX LABS INC | Combination immediate release controlled release levodopa/carbidopa dosage forms |
May, 2022
(1 year, 10 months ago) | |
US9463246 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US8377474 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US8557283 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US8454998 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US9533046 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US9901640 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US9089607 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) | |
US9089608 | IMPAX LABS INC | Controlled release formulations of levodopa and uses thereof |
Dec, 2028
(4 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Jan 07, 2018 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 January, 2015
Treatment: Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication; Treatment of parkinson's disease; Treatment o...
Dosage: CAPSULE, EXTENDED RELEASE;ORAL